Torrent Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018
January 30, 2019 at 06:13 am
Share
Torrent Pharmaceuticals Ltd. announced earnings results for the third quarter and nine months ended December 31, 2018. For the third quarter, the company announced total revenue was INR 20,540 million compared to INR 15,370 million a year ago. Net income was INR 2,460 million compared to INR 580 million a year ago. Basic earnings per share was INR 14.5 compared to INR 3.37 a year ago.
For the nine months, total revenue was INR 58,570 million compared to INR 44,990 million a year ago. Net income was INR 5,880 million compared to INR 4,500 million a year ago. Basic earnings per share was INR 34.73 compared to INR 26.53 a year ago.
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
TORRENT PHARMACEUTICALS LIMITED 
